Sickle cell disease (SCD), the most common inherited blood disorder, affects millions worldwide. In the United States alone, ...

The underutilization of disease-modifying therapy by people with sickle cell disease is “persistent and alarming,” according ...

Sickle Cell Disease Treatment Market is estimated to be valued at USD 3.20 Bn in 2025 and is expected to reach USD 8.81 Bn by 2032 exhibiting a CAGR of 15.6% Mr. Shah Coherent Market Insights Pvt. Ltd ...

Oppenheimer analyst Matthew Biegler met with Fulcrum Therapeutics (FULC)’ management Tuesday after the company reported year-end financials.

TANZANIA: SICKLE Cell Disease (SCD) remains a significant health burden, particularly in Africa where approximately 80 per ...

NITI Aayog's committee, chaired by V K Paul, aims to transform AIIMS New Delhi into a top medical research and practice ...

Government think tank NITI Aayog has formed a committee to create a roadmap aimed at transforming AIIMS, New Delhi, into a ...

BESREMi is a preferred, FDA-approved option for both symptomatic low- and high-risk polycythemia vera patients. In the polycythemia vera space, BESREMi faces competition from drugs like ruxolitinib, a ...

When Vijay Sankaran was an MD-PhD student at Harvard Medical School in the mid-2000s, one of his first clinical encounters was with a 24-year-old ...